FDA Urges Sponsors to Give Greater Consideration to Patient-Reported Outcome Assessments

Drug Industry Daily
A A
Drug sponsors conducting a clinical trial should take efforts to better understand the effects of a particular disease on patients when designing ways to measure patient-reported outcomes, says an FDA clinical trials official.

To View This Article:

Login

Subscribe To Drug Industry Daily